Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
This is a long-term extension study of HSK44459-202 in eligible participants who have completed the Week 12 visit of the originating Study HSK44459-202. The total duration of this study will be up to 56 weeks which will include a 52-week treatment period, and a 4-week safety follow-up period after the last study intervention administration. Safety will be assessed by the incidence and severity of adverse events during the study.
Official title: A Multicenter, Open-label Study to Evaluate the Long-term Safety and Efficacy of HSK44459 Tablets for the Treatment of Patients With Bechet's Disease
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-07
Completion Date
2027-07
Last Updated
2025-07-17
Healthy Volunteers
No
Conditions
Interventions
HSK44459 tablets
Orally, twice a day